Meeting
2020 ASCO Virtual Scientific Program
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
Authors
Christine H. Chung
Moffit Cancer Center, Tampa, FL
Christine H. Chung , Marcelo Raul Bonomi , Conor Ernst Steuer , Michael J. Schell , Jiannong Li , Matthew Johnson , Jude Masannat , Juan C. Hernandez-Prera , Caitlin McMullen , J Wadsworth , Krupal Patel , Julie Ann Kish , Jameel Muzaffar , Kedar Kirtane , James William Rocco , Nabil F. Saba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03370276
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6515)
DOI
10.1200/JCO.2020.38.15_suppl.6515
Abstract #
6515
Poster Bd #
176
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2022 ASCO Annual Meeting
CA209-9KY: Results of a phase II study of intensity modulated radiotherapy (IMRT) re-irradiation and concurrent/adjuvant nivolumab (nivo) in patients with loco-regionally recurrent or second primary (RSPT) head and neck squamous cell carcinoma (HNSCC).
First Author: Nabil F. Saba